Adjuvant Chemotherapy in Uterine Leiomyosarcoma: Trends and Factors Impacting Usage

Table 2

Multivariate predictors of chemotherapy receipt in nonmetastatic uterine LMS.

Variable	OR	95% CI
Year of diagnosis
Per year increase	1.16	1.13–1.20	<0.0001
Age at diagnosis, y
18–39	Ref
40–49	0.93	0.67–1.31	0.6927
50–64	0.93	0.67–1.29	0.6537
65+	0.60	0.38–0.94	0.0264
Race
White	Ref
African American	0.80	0.63–1.02	0.0727
Other	1.09	0.78–1.53	0.5965
Hispanic
Yes	1.34	0.94–1.91	0.1112
No	Ref
Comorbidities (Charlson/Deyo score)
0	Ref
1	0.93	0.73–1.18	0.5332
2	0.72	0.37–1.41	0.3381
Insurance status
Private	Ref
Medicare	0.59	0.42–0.84	0.0030
Medicaid	1.06	0.77–1.48	0.7062
None	0.92	0.64–1.30	0.6265
Other government	2.42	1.04–5.61	0.0400
Education (% no high school diploma)
≥21	0.68	0.48–0.97	0.0354
13–20.9	0.58	0.43–0.79	0.0005
7–12.9	0.86	0.68–1.09	0.2143
<7	Ref
Median household income ($)
<38,000	1.49	1.04–2.13	0.0282
38,000–47,999	1.42	1.05–1.92	0.0239
48,000–62,999	1.37	1.07–1.75	0.0117
>63,000	Ref
Location of patient
Large metropolitan	Ref
Small metropolitan	0.92	0.73–1.15	0.4570
Suburban	1.00	0.73–1.39	0.9764
Rural	0.69	0.43–1.10	0.1146
Hospital volume (cases per year)
0.09	Ref
0.18–0.27	1.00	0.62–1.61	0.9964
0.36–0.55	1.18	0.74–1.87	0.4912
0.64–7.27	1.27	0.82–1.98	0.2812
Regional lymph nodes positive
Yes	3.83	1.81–8.09	0.0004
No	Ref
Stage
I	0.32	0.25–0.41	<0.0001
II	0.38	0.26–0.56	<0.0001
III	Ref
Hormone therapy
Yes	0.72	0.30–1.70	0.4473
No	Ref
Radiation
Yes	1.45	1.17–1.79	0.0006
No	Ref
Oophorectomy
Yes	0.92	0.72–1.19	0.5395
No	Ref